Market capitalization | $24.72m |
Enterprise Value | $16.92m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.54 |
P/S ratio (TTM) P/S ratio | 6.63 |
P/B ratio (TTM) P/B ratio | 2.54 |
Revenue growth (TTM) Revenue growth | -70.78% |
Revenue (TTM) Revenue | $3.73m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
1 Analyst has issued a forecast Marker Therapeutics, Inc.:
1 Analyst has issued a forecast Marker Therapeutics, Inc.:
Jun '24 |
+/-
%
|
||
Net Profit | -2.19 -2.19 |
65%
65%
|
|
Depreciation and Amortization | - - |
-
|
|
Stock Compensation | 0.06 0.06 |
150%
150%
|
|
Operating Cash Flow | -3.57 -3.57 |
50%
50%
|
|
Investments | - - |
-
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -3.57 -3.57 |
50%
50%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Head office | United States |
CEO | Juan Vera |
Employees | 8 |
Founded | 1991 |
Website | www.markertherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.